



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Keith Weinstock and David Bush

Application No.:

10/603,113

Group Art Unit:

1645

Filed:

June 24, 2003

Examiner:

Zeman, Robert

Title:

Nucleic Acid and Amino Acid Sequences Relating to *Candida albicans* for
Diagnostics and Therapeutics

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450	
on <u>12/19/06</u>	<u>Kimberly D. LaSelva</u>
Date	Signature
<u>Kimberly D. LaSelva</u>	
Typed or printed name of person signing certificate	

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is submitted:

☐ under 37 CFR 1.129(a), or
(First/Second submission after Final Rejection)

☒ under 37 CFR 1.97(b), or
(Within three months of filing national application; or date of entry of the national stage in international application; or before mailing date of first office action on the merits; whichever occurs last)

☐ under 37 CFR 1.97(c) together with either:
☐ a Statement under 37 CFR 1.97(e), as checked below, or
☐ a \$240.00 fee under 37 CFR 1.17(p), or
(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

☐ under 37 CFR 1.97(d) together with:
☐ a Statement under 37 CFR 1.97(e), as checked below, and
☐ a Petition under 37 CFR 1.97(d)(2), and
☐ a \$130.00 petition fee set forth in 37 CFR 1.17(i).
(Filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee)

☐ Applicant requests that the attached IDS and cited reference(s) _____ be placed in the application filewrapper.
(Filed after payment of issue fee)

Statement Under 37 CFR 1.97(e)

- ☐ Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Enclosed herewith is form PTO-1449:

- ☐ Copies of the cited references are enclosed.
- ☒ Copies of cited references are enclosed except those entered in prior application, U.S. Serial No. 09/248,796, and references that are not required to be submitted under 37 CFR 1.98.
- ☐ The listed references were cited in the enclosed International Search Report in a counterpart foreign application.

Concise Explanation Requirement (non-English references):

- ☐ The "concise explanation" requirement for reference(s) _____ under 37 CFR 1.98(a)(3) is satisfied by:
- ☐ the explanation provided on the attached sheet.
- ☐ the explanation provided in the Specification.
- ☐ submission of the enclosed International Search Report.
- ☐ the enclosed English language abstract.


It is requested that the information disclosed herein be made of record in this application.

Method of payment:


- ☐ Enclosed is a check in the amount of \$ _____.
- ☐ Please charge Deposit Account 501040 in the amount of \$ _____.
- ☐ A copy of this Statement is enclosed.
- ☒ Please charge any deficiency in fees and credit any overpayment to Deposit Account 501040.

Respectfully submitted,

OSCIENT PHARMACEUTICALS CORPORATION

By 
Robert L. Spadafora, Esq.
Registration No. 46,197
Telephone (781) 398-2300
Facsimile (781) 398-2530

Waltham, Massachusetts 02451
Dated: 12/17/06



PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.
PATH 03-13APPLICATION NO.
10/603,113INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

APPLICANT
Weinstock, et al.FILING DATE
06/24/03GROUP
1645

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AL						
	AM						
	AN						
	AO						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AR	GAUR et al., Expression, Cloning, and Characterization of a Candida albicans Gene, ALA1, That Confers Adherence Properties upon Saccharomyces cerevisiae for Extracellular Matrix Proteins, Infection and Immunity, 65(12): 5289-5294; 1997.
AS	HOYER et al., Candida albicans ALS3 and insights into the nature of the ALS gene family, Curr. Genet., 33: 451-459; 1998.
AT	HOYER et al., Candida albicans ALS1: domains regulated to a Saccharomyces cerevisiae sexual agglutinin separated by a repeating motif, Molecular Microbiology, 15(1): 39-54; 1995.
AU	GERHOLD et al., It's the genes! EST access to human genome content, BioEssays 18(12): 973-981; 1996.
AV	WELLS et al., The chemokine information source: identification and characterization of novel chemokines using the WorldWideWeb and Expressed Sequence Tag Databases, J. Leukoc. Biol. 61: 545-550; 1997.
AW	RUSSELL et al., Structural Features can be Unconserved in Proteins with Similar Folds, J. Mol. Biol. 244: 332-350; 1994.
AX	1990 Sigma Chemical Company Catalog [Published by Sigma Chemical Company, P.O. Box 14508, St. Louis, Missouri] pp 776-778, 1990.
AY	GILLUM et al., Isolation of the Candida albicans gene for orotidine-5'-phosphate decarboxylase by Complementation of S. cerevisiae ura3 and E. coli pyrF Mutations, Mol. Gen. Genet., 198:179-182; 1984.

EXAMINER

DATE CONSIDERED